Literature DB >> 33221944

The clinical value of ceMRA versus DSA for follow-up of intracranial aneurysms treated by coil embolization: an assessment of occlusion classifications and impact on treatment decisions.

Maximilian Patzig1, Robert Forbrig2, Margaretha Gruber2, Thomas Liebig2, Franziska Dorn2.   

Abstract

OBJECTIVE: The aim of this study was a detailed analysis of the value of contrast-enhanced magnetic resonance angiography (ceMRA) compared to digital subtraction angiography (DSA) for follow-up imaging of intracranial aneurysms treated by coil embolization.
METHODS: Patients with coiled aneurysms and follow-up exams including both DSA and 3 T ceMRA were retrospectively identified. In blinded readings, both modalities were graded according to the modified Raymond-Roy classification (MRRC) and the Meyers scale. Additionally, readers were asked to make a decision regarding retreatment/follow-up based on the respective imaging findings.
RESULTS: The study comprised 92 patients harboring 102 coiled aneurysms. There was good intermethod agreement of DSA and ceMRA concerning both the MRRC (κ = 0.64) and the Meyers scale (κ = 0.74). Agreement regarding occlusion of < 90% of the aneurysm (Meyers grade ≥ 2) was very good (κ = 0.87). Regarding the detection of a remnant with contrast between the coil mass and the aneurysm wall (MRRC IIIb), there were 12 discrepant findings and agreement was good (κ = 0.70). Comparing treatment/follow-up decisions, the two methods agreed very well (κ = 0.92). In seven patients with discrepant treatment decisions, the authors concurred with DSA in four cases and with ceMRA in three cases when evaluating both modalities together. Interval aneurysm growth was found in more cases with ceMRA (n = 19) than with DSA (n = 16).
CONCLUSIONS: CeMRA is very unlikely to miss a relevant aneurysm remnant and thus could be suitable as the primary follow-up method. In case of remnant growth or recurrence, however, additional DSA might be required to guide treatment decisions. KEY POINTS: • There is high accordance between ceMRA and DSA regarding the evaluation of intracranial aneurysms treated by endovascular coil embolization, but closer analysis also revealed relevant differences. • CeMRA could be suitable as the primary follow-up imaging modality, potentially eliminating the need for routine DSA. • DSA will still be required in case of aneurysm remnant growth or recurrence as detected by ceMRA.

Entities:  

Keywords:  Angiography; Digital subtraction; Endovascular procedures; Intracranial aneurysm; Magnetic resonance angiography

Mesh:

Year:  2020        PMID: 33221944     DOI: 10.1007/s00330-020-07492-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  31 in total

Review 1.  Current imaging assessment and treatment of intracranial aneurysms.

Authors:  Lotfi Hacein-Bey; James M Provenzale
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

2.  Risk of cerebral angiography in patients with subarachnoid hemorrhage, cerebral aneurysm, and arteriovenous malformation: a meta-analysis.

Authors:  H J Cloft; G J Joseph; J E Dion
Journal:  Stroke       Date:  1999-02       Impact factor: 7.914

Review 3.  Imaging Follow-Up of Intracranial Aneurysms Treated by Endovascular Means: Why, When, and How?

Authors:  Sebastien Soize; Matthias Gawlitza; Hélène Raoult; Laurent Pierot
Journal:  Stroke       Date:  2016-03-29       Impact factor: 7.914

4.  Treatment of ruptured and unruptured cerebral aneurysms in the USA: a paradigm shift.

Authors:  Ning Lin; Kevin S Cahill; Kai U Frerichs; Robert M Friedlander; Elizabeth B Claus
Journal:  J Neurointerv Surg       Date:  2011-06-23       Impact factor: 5.836

Review 5.  Endovascular treatment of intracranial unruptured aneurysms: systematic review and meta-analysis of the literature on safety and efficacy.

Authors:  Olivier N Naggara; Phil M White; François Guilbert; Daniel Roy; Alain Weill; Jean Raymond
Journal:  Radiology       Date:  2010-07-15       Impact factor: 11.105

Review 6.  Intracranial Aneurysms: Recurrences More than 10 Years after Endovascular Treatment-A Prospective Cohort Study, Systematic Review, and Meta-Analysis.

Authors:  Augustin Lecler; Jean Raymond; Christine Rodriguez-Régent; Fawaz Al Shareef; Denis Trystram; Sylvie Godon-Hardy; Wagih Ben Hassen; Jean-François Meder; Catherine Oppenheim; Olivier N Naggara
Journal:  Radiology       Date:  2015-06-09       Impact factor: 11.105

7.  Age-related trends in the treatment and outcomes of ruptured cerebral aneurysms: a study of the nationwide inpatient sample 2001-2009.

Authors:  W Brinjikji; G Lanzino; A A Rabinstein; D F Kallmes; H J Cloft
Journal:  AJNR Am J Neuroradiol       Date:  2012-11-01       Impact factor: 3.825

Review 8.  Neurologic complications of cerebral angiography: prospective analysis of 2,899 procedures and review of the literature.

Authors:  Robert A Willinsky; Steve M Taylor; Karel TerBrugge; Richard I Farb; George Tomlinson; Walter Montanera
Journal:  Radiology       Date:  2003-03-13       Impact factor: 11.105

Review 9.  Coiling of intracranial aneurysms: a systematic review on initial occlusion and reopening and retreatment rates.

Authors:  Sandra P Ferns; Marieke E S Sprengers; Willem Jan van Rooij; Gabriël J E Rinkel; Jeroen C van Rijn; Shandra Bipat; Menno Sluzewski; Charles B L M Majoie
Journal:  Stroke       Date:  2009-06-11       Impact factor: 7.914

10.  The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT).

Authors:  Andrew J Molyneux; Jacqueline Birks; Alison Clarke; Mary Sneade; Richard S C Kerr
Journal:  Lancet       Date:  2014-10-28       Impact factor: 79.321

View more
  1 in total

1.  Differential Subsampling with Cartesian Ordering-MRA for Classifying Residual Treated Aneurysms.

Authors:  P Shahrouki; R Gupta; P Belani; A Chien; A H Doshi; R De Leacy; J T Fifi; J Mocco; K Nael
Journal:  AJNR Am J Neuroradiol       Date:  2022-06       Impact factor: 4.966

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.